Review Meibomian Gland Dysfunction: Emerging Diagnostic Technologies and Novel Therapeutic Approaches
DOI:
https://doi.org/10.12775/JEHS.2026.95.73540Keywords
meibomian, meibomian gland dysfunction, dry eye disease, evaporative dry eye, meibography, treatment, tear filmAbstract
Meibomian gland dysfunction (MGD) is a chronic disorder of the eyelid margin and the leading cause of evaporative dry eye disease (EDE). Alterations in meibum secretion impair tear film stability, increase tear evaporation, and contribute to ocular surface inflammation and visual disturbances. This narrative review summarizes current knowledge regarding the anatomy and physiology of the meibomian glands, the pathophysiology of MGD, its relationship with dry eye disease (DED), contemporary diagnostic methods, and available treatment options. Recent advances in meibography, interferometry, lipid layer assessment, and artificial intelligence have improved diagnostic capabilities. In addition to conventional therapies, including eyelid hygiene, warm compresses, and anti-inflammatory treatment, device-based interventions such as thermal pulsation therapy, intense pulsed light, and low-level light therapy have expanded therapeutic possibilities. Emerging regenerative approaches may further improve future management strategies. Continued advances in diagnosis and treatment are expected to support more personalized and mechanism-based care for patients with MGD.
References
1. Butovich IA. Meibomian glands, meibum, and meibogenesis. Exp Eye Res. 2017;163:2-16. doi:10.1016/j.exer.2017.06.020
2. Wang LX, Deng YP. Androgen and meibomian gland dysfunction: from basic molecular biology to clinical applications. Int J Ophthalmol. 2021;14(6):915-922. doi:10.18240/ijo.2021.06.18.
3. Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65(2):205-217. doi:10.1016/j.survophthal.2019.08.007
4. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929. doi:10.1167/iovs.10-6997a
5. Sheppard, J.D., Nichols, K.K. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape. Ophthalmol Ther 12, 1397–1418 (2023). doi:10.1007/s40123-023-00669-1
6. Tsubota K, Pflugfelder SC, Liu Z, et al. Defining Dry Eye from a Clinical Perspective. Int J Mol Sci. 2020;21(23):9271. doi:10.3390/ijms21239271.
7. Wolffsohn, James & Lingham, Gareth & Downie et al. (2023). TFOS Lifestyle: Impact of the digital environment on the ocular surface. The Ocular Surface. 28. doi:10.1016/j.jtos.2023.04.004.
8. Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55(1):241-252. doi:10.1080/07853890.2022.2157477.
9. Wolffsohn JS, et al. TFOS DEWS III Diagnostic Methodology Report. Am J Ophthalmol. 2025;279:387-450. doi:10.1016/j.ajo.2025.05.033
10. Narang P, et al. Evaporative dry eye disease due to meibomian gland dysfunction: Preferred practice pattern guidelines. Indian J Ophthalmol. 2023. doi:10.4103/IJO.IJO_2841_22
11. Pastor-Zaplana JA, et al. OSDI Questions on Daily Life Activities Allow to Detect Subclinical Dry Eye in Young Contact Lens Users. J Clin Med. 2022;11:2626. doi:10.3390/jcm11092626
12. Herbaut A, Baudouin C, Labbé A. Tear film analysis and evaluation of optical quality: a review. J Fr Ophtalmol. 2019;42:e21-e35. doi:10.1016/j.jfo.2018.12.001
13. Choi M, et al. Meibum expressibility improvement as a therapeutic target of intense pulsed light treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines. Sci Rep. 2019;9:7648. doi:10.1038/s41598-019-44000-0
14. Pult H, Nichols JJ. A review of meibography. Optom Vis Sci. 2012;89:E760-E769. doi:10.1097/OPX.0b013e318269caa5
15. Arita R, et al. Tear interferometric patterns reflect clinical tear dynamics in dry eye patients. Invest Ophthalmol Vis Sci. 2016;57:3928-3934. doi:10.1167/iovs.15-18627
16. Kim WJ, et al. Lipid layer thickness decrease due to meibomian gland dysfunction leads to tear film instability and reflex tear secretion. Ocul Immunol Inflamm. 2022. doi:10.1080/07853890.2022.2056238
17. Ye F, et al. Objective optical assessment of tear-film quality dynamics in patients with meibomian gland dysfunction. Indian J Ophthalmol. 2019;67:1226-1231. doi:10.4103/ijo.IJO_1278_18
18. Kumar NR, et al. Tear biomarkers in dry eye disease. Indian J Ophthalmol. 2023. doi:10.4103/IJO.IJO_2981_22
19. Swiderska K, Read ML, Blackie CA, et al. Latest developments in meibography: A review. Ocul Surf. 2022. doi:10.1016/j.jtos.2022.06.002
20. Li L, Xiao K, Shang X, et al. Advances in artificial intelligence for meibomian gland evaluation: A comprehensive review. Surv Ophthalmol. 2024. doi:10.1016/j.survophthal.2024.07.005
21. Pucker AD, Yim TW, Rueff E, et al. LipiFlow for the treatment of dry eye disease. Cochrane Database Syst Rev. 2024;(2). doi:10.1002/14651858.CD015448.pub2
22. Cote S, Zhang AC, Ahmadzai V, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020;(3). doi:10.1002/14651858.CD013559
23. Park Y, Kim H, Kim S, et al. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial. Sci Rep. 2022;12:3575. doi:10.1038/s41598-022-07427-6
24. Magno M, Moschowits E, Arita R, et al. Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction. Surv Ophthalmol. 2021;66(4):612-622. doi:10.1016/j.survophthal.2020.11.005
25. He CZ, Zeng ZJ, Liu JQ, et al. Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials. Front Med. 2024;11:1430785. doi:10.3389/fmed.2024.1430785
26. Mederle AL, Andrei D, Ghenciu LA, et al. Comparative efficacy of platelet-rich plasma, autologous serum, and artificial tears in dry eye disease: a systematic review and meta-analysis. Biomedicines. 2025;13:2316. doi:10.3390/biomedicines13092316
27. Zhang D, Chen T, Liang Q, et al. A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease. Stem Cell Res Ther. 2025;16:202. doi:10.1186/s13287-025-04292-8
28. Yu F, Zhao X, Wang Q, et al. Photothermal-responsive soluble microneedle patches for meibomian gland dysfunction therapy. Adv Sci. 2025;12:2413962. doi:10.1002/advs.202413962
29. Gurnani B, Kaur K. Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care. Ophthalmol Ther. 2026;15:1561-1584. doi:10.1007/s40123-026-01354-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Brajan Roczyński, Izabela Polok, Oliwia Pniewska, Paulina Polok

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 129
Number of citations: 0